The experimental drug fenebrutinib was shown to significantly outperform Aubagio (teriflunomide), an approved therapy, in reducing relapses and MRI markers of disease activity in people with relapsing forms of multiple sclerosis (MS). That’s according to new data from a pair of largely identical Phase 3 clinical trials testing the oral BTK inhibitor globally in adults […]
The post AAN 2026: Fenebrutinib outperforms Aubagio for treating relapsing MS appeared first on Multiple Sclerosis News Today.
Source: multiplesclerosisnewstoday.com